IL212175B - Antibodies *1muc - Google Patents

Antibodies *1muc

Info

Publication number
IL212175B
IL212175B IL212175A IL21217511A IL212175B IL 212175 B IL212175 B IL 212175B IL 212175 A IL212175 A IL 212175A IL 21217511 A IL21217511 A IL 21217511A IL 212175 B IL212175 B IL 212175B
Authority
IL
Israel
Prior art keywords
muc1
antibodies
Prior art date
Application number
IL212175A
Other languages
English (en)
Hebrew (he)
Other versions
IL212175A0 (en
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of IL212175A0 publication Critical patent/IL212175A0/en
Publication of IL212175B publication Critical patent/IL212175B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL212175A 2008-10-06 2011-04-06 Antibodies *1muc IL212175B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10320408P 2008-10-06 2008-10-06
PCT/US2009/059754 WO2010042562A2 (en) 2008-10-06 2009-10-06 Muc1* antibodies

Publications (2)

Publication Number Publication Date
IL212175A0 IL212175A0 (en) 2011-06-30
IL212175B true IL212175B (en) 2019-08-29

Family

ID=42101177

Family Applications (1)

Application Number Title Priority Date Filing Date
IL212175A IL212175B (en) 2008-10-06 2011-04-06 Antibodies *1muc

Country Status (8)

Country Link
US (4) US20170204191A1 (cg-RX-API-DMAC7.html)
EP (3) EP4083072A1 (cg-RX-API-DMAC7.html)
JP (3) JP2012504961A (cg-RX-API-DMAC7.html)
KR (1) KR101455447B1 (cg-RX-API-DMAC7.html)
CN (1) CN102239182B (cg-RX-API-DMAC7.html)
CR (1) CR20110238A (cg-RX-API-DMAC7.html)
IL (1) IL212175B (cg-RX-API-DMAC7.html)
WO (1) WO2010042562A2 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4083072A1 (en) 2008-10-06 2022-11-02 Minerva Biotechnologies Corporation Muc1* antibodies
US11898160B2 (en) * 2008-10-09 2024-02-13 Minerva Biotechnologies Corporation Method for maintaining pluripotency in cells
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
EP3228629A1 (en) * 2010-06-16 2017-10-11 Minerva Biotechnologies Corporation Reprogramming cancer cells
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
EP2686418A4 (en) * 2011-03-17 2015-04-22 Minerva Biotechnologies Corp METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
CN102716472A (zh) * 2011-03-31 2012-10-10 李光辉 一种肿瘤疫苗及其合成方法
AU2013289913A1 (en) * 2012-07-13 2015-03-05 Minerva Biotechnologies Corporation Method for inducing cells to less mature state
CN104717980A (zh) * 2012-08-14 2015-06-17 米纳瓦生物技术公司 干细胞增强疗法
US9770011B2 (en) 2012-09-29 2017-09-26 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
CA2898239A1 (en) * 2013-01-23 2014-07-31 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
JP6908381B2 (ja) 2014-01-29 2021-07-28 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１−ｃ／細胞外ドメイン（ｍｕｃ１−ｃ／ｅｃｄ）に対する抗体
CN103880956B (zh) * 2014-03-10 2015-12-30 中国人民解放军第四军医大学 抗muc1单克隆抗体及其轻链和重链可变区
EP4050103A1 (en) 2014-04-07 2022-08-31 Minerva Biotechnologies Corporation Anti-nme antibody
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
AU2015316522B2 (en) * 2014-09-16 2021-01-21 Symphogen A/S Anti-met antibodies and compositions
KR102390359B1 (ko) * 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
US20180148514A1 (en) 2014-10-02 2018-05-31 City Of Hope Multivalent meditopes, meditope-binding antibodies and uses thereof
WO2016057683A2 (en) * 2014-10-07 2016-04-14 Ann And Robert H. Lurie Children's Hospital Of Chicago Novel anti-nodal antibodies and methods of using same
AU2016219350A1 (en) 2015-02-10 2017-08-24 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
MX2018006973A (es) * 2015-12-09 2019-05-16 Corvus Pharmaceuticals Inc Anticuerpos anti-cd73 humanizados.
EP4245775A3 (en) * 2016-04-29 2023-11-15 Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
US20190343953A1 (en) * 2017-01-27 2019-11-14 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
CN110650976B (zh) * 2017-04-13 2024-04-19 赛罗帕私人有限公司 抗SIRPα抗体
CN109971713B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 稳定表达PD-1抗体的Muc1特异性CAR-T细胞及其用途
BR112020016005A2 (pt) * 2018-02-07 2020-12-15 Regeneron Pharmaceuticals, Inc. Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio
US20200405832A1 (en) * 2018-03-09 2020-12-31 Minerva Biotechnologies Corporation Method for anti-muc1* car t cell stimulation
CN120484122A (zh) * 2019-01-11 2025-08-15 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
WO2020163325A1 (en) 2019-02-04 2020-08-13 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
EP4161970A4 (en) 2020-06-08 2024-07-10 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS FOR TREATING CANCER OR CANCER METASTASES
IL299332A (en) 2020-06-26 2023-02-01 Minerva Biotechnologies Corp Anti-nme antibody and method of treating cancer or cancer metastasis
IL299903A (en) * 2020-07-16 2023-03-01 Dana Farber Cancer Inst Inc Antibodies against the MUC1-C/EXTRACELLULAR domain (MUC1-C/ECD)
EP4188432A4 (en) * 2020-07-31 2024-08-21 R.P. Scherer Technologies, LLC ANTIBODY SPECIFIC FOR MUCIN-1 AND METHODS OF USE THEREOF
CN119317447A (zh) 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
EP4646444A1 (en) * 2023-01-04 2025-11-12 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-muc1 antibodies and uses thereof
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases
WO2025080693A1 (en) 2023-10-11 2025-04-17 Minerva Biotechnologies Corporation Anti-muc1* antibody drug complexes and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US20020136725A1 (en) * 1996-01-17 2002-09-26 Smithkline Beecham Corporation Antithrombotic agents
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
DE69941031D1 (de) 1998-11-12 2009-08-06 Novolytics Inc Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion
US20020064528A1 (en) * 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
US20020052311A1 (en) * 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US20020146750A1 (en) * 2000-03-30 2002-10-10 Hoogenboom Hendricus R.J.M. Mucin-1 specific binding members and methods of use thereof
DE60130891T2 (de) 2000-06-29 2008-07-17 Anthera Pharmaceuticals Inc., San Mateo Heilmittel für krebs
DE60140461D1 (de) * 2000-09-11 2009-12-24 Genzyme Corp Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren
DK2322929T3 (en) * 2000-11-27 2016-07-25 Minerva Biotechnologies Corp Diagnostics, pharmaceutical screening and treatment of cancer
JP2005508839A (ja) * 2001-03-29 2005-04-07 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ペプチドおよびｍｕｃ１タンパク質に対する抗体
US7630836B2 (en) 2001-05-30 2009-12-08 The Kitasato Institute Polynucleotides
JP2005507876A (ja) 2001-09-05 2005-03-24 ミナーバ バイオテクノロジーズ コーポレイション 癌を治療する組成物および方法
WO2003074566A2 (en) 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
JP2006504630A (ja) 2002-04-22 2006-02-09 ダイアックス コーポレイション ムチンポリペプチドに特異的な抗体
KR101143035B1 (ko) * 2002-06-14 2012-05-08 이뮤노메딕스, 인코오포레이티드 단클론 항체 ｈＰＡＭ4
EP2363410B1 (en) 2002-11-27 2017-10-11 Minerva Biotechnologies Corporation Isoforms of MUC1
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US20060173171A1 (en) 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
EP3653641A1 (en) 2004-02-19 2020-05-20 Genentech, Inc. Cdr-repaired antibodies
JP4937127B2 (ja) * 2004-10-04 2012-05-23 ジェネンテック， インコーポレイテッド 肝細胞成長因子活性化物質のモジュレータ
EP1875244B1 (en) * 2005-03-30 2019-01-23 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
CN101652469B (zh) 2006-12-06 2014-04-16 米纳瓦生物技术公司 用于鉴定和操作细胞的方法
WO2008073817A2 (en) * 2006-12-08 2008-06-19 Dana-Farber Cancer Institute, Inc. Muc1 and galectin-3
EP4083072A1 (en) 2008-10-06 2022-11-02 Minerva Biotechnologies Corporation Muc1* antibodies
CN104717980A (zh) * 2012-08-14 2015-06-17 米纳瓦生物技术公司 干细胞增强疗法
AU2016219350A1 (en) * 2015-02-10 2017-08-24 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies

Also Published As

Publication number Publication date
IL212175A0 (en) 2011-06-30
EP2337801A4 (en) 2012-07-25
US11560435B2 (en) 2023-01-24
US20170204191A1 (en) 2017-07-20
US20230295340A1 (en) 2023-09-21
EP3130607B1 (en) 2024-04-17
JP6392923B2 (ja) 2018-09-19
EP3130607A2 (en) 2017-02-15
JP2012504961A (ja) 2012-03-01
CN102239182A (zh) 2011-11-09
WO2010042562A2 (en) 2010-04-15
EP4083072A1 (en) 2022-11-02
WO2010042562A3 (en) 2010-09-30
KR20110067153A (ko) 2011-06-21
JP6230983B2 (ja) 2017-11-15
EP2337801A2 (en) 2011-06-29
US20180222998A1 (en) 2018-08-09
JP2015071614A (ja) 2015-04-16
JP2017176174A (ja) 2017-10-05
EP3130607A3 (en) 2017-06-28
US10421819B2 (en) 2019-09-24
CR20110238A (es) 2012-05-29
KR101455447B1 (ko) 2014-10-27
CN102239182B (zh) 2014-07-09
US20200239594A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
IL212175A0 (en) Muc1* antibodies
ZA201200166B (en) Muc1 antibodies
GB0821100D0 (en) Antibodies
EP2241578A4 (en) ANTI-CLDN6 ANTIBODIES
ZA201102119B (en) Improved antibody libraies
AP3371A (en) Anti-IGF antibodies
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
GB0708002D0 (en) Antibodies
ZA201100300B (en) Anti-cd5 antibodies
IL212701A0 (en) Improved anti-cd19 antibodies
SI2262831T1 (sl) Protitelesa anti-properdina
SI2200700T1 (sl) Nova protitelesa
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
IL207581A0 (en) Anti-tyrp1 antibodies
GB0718737D0 (en) Antibodies
IL236236A (en) Antibodies to the fam26f polypeptide
GB0702888D0 (en) Novel Antibodies
GB0920324D0 (en) Antibodies
GB0905972D0 (en) Antibodies against IL-17BR
ZA201007976B (en) Anti-pirb antibodies
GB0816976D0 (en) Protein
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
GB0818356D0 (en) Antibodies

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed